Candida albicans Antibodies (IgG, IgA, IgM)
The Candida albicans Antibodies test measures serum IgG, IgA, and IgM responses to Candida albicans, a commensal yeast that can cause mucosal and invasive infections. IgM suggests acute infection, IgG reflects past or chronic exposure, and IgA indicates mucosal immune activation.
3
Biomarkers
Blood (serum)
Sample
3–5 business days
Turnaround
No
Fasting
What is the Candida Antibodies test?
The Candida albicans Antibodies (IgG, IgA, IgM) test measures serum immunoglobulin responses to Candida albicans, a ubiquitous commensal yeast that can cause mucosal and invasive infections under conditions of immune compromise, barrier disruption, or ecological dysbiosis. Practitioners order this panel to support the investigation of recurrent or chronic mucocutaneous candidiasis, to assess suspected systemic candidiasis in immunocompromised patients when direct culture or antigen tests are pending or negative, and occasionally to evaluate patients with chronic gastrointestinal symptoms attributed to putative intestinal candida overgrowth. The three immunoglobulin classes provide temporal and compartment-specific information: IgM suggests acute infection, IgG reflects past exposure or chronic infection, and IgA is linked to mucosal immune activation. Because Candida colonises the gut and mucosa of most individuals, antibody seropositivity — especially IgG — is common in asymptomatic populations, so results must be interpreted in the context of clinical presentation, microbial culture, and other diagnostic findings rather than as standalone proof of infection.
What does the Candida Antibodies test measure?
IgG antibodies to Candida albicans develop following exposure to the organism and reflect historical or ongoing systemic immune response. Candida is a commensal yeast resident in the gastrointestinal and genitourinary tracts of most healthy individuals, held in check by local immune defences and microbial competition. IgG responses arise during mucosal or invasive candidiasis and persist for months to years, so seropositivity is common in the general population and indicates exposure rather than active disease.
Elevated Candida IgG is interpreted in the context of clinical presentation. It may suggest chronic or recurrent mucocutaneous candidiasis, or contribute to the evaluation of suspected invasive candidiasis when combined with culture, mannan antigen, or beta-D-glucan. However, IgG alone cannot distinguish colonisation from infection, and many asymptomatic individuals carry low-titre antibodies from prior exposure.
IgA is the dominant immunoglobulin at mucosal surfaces and is produced locally in response to Candida colonisation or overgrowth in the gastrointestinal, respiratory, or genitourinary epithelium. Serum IgA reflects mucosal immune activation translocating into the circulation, and elevated titres may indicate ongoing mucosal candidiasis or increased gut permeability permitting yeast-antigen absorption.
Elevated Candida IgA is used by some practitioners as a marker of mucosal candidiasis, particularly in the gastrointestinal tract. Chronic mucosal inflammation, disrupted barrier function, and immune dysregulation may all drive IgA production. However, the clinical validity of IgA serology for diagnosing 'intestinal candida overgrowth' outside overt thrush or oesophagitis is debated, and results must be contextualised with clinical symptoms and direct mucosal assessment where feasible.
IgM antibodies are the earliest immunoglobulin class produced in response to a new or acute infection. In the context of Candida, IgM may be elevated during acute invasive candidiasis or during the first encounter with the organism, though most immunocompetent adults have had prior Candida exposure and carry IgG without IgM.
Elevated Candida IgM may suggest acute or reactivated infection, particularly in the setting of invasive candidiasis in immunocompromised patients. Its sensitivity and specificity for invasive disease are limited, however, and IgM results are best interpreted alongside culture, imaging, and other fungal biomarkers. Isolated IgM elevation in an immunocompetent patient without clear clinical candidiasis may reflect recent mucosal infection or assay cross-reactivity.
Why is the Candida Antibodies test ordered?
- Investigation of recurrent or refractory oral, oesophageal, or vulvovaginal candidiasis when local culture is impractical or negative
- Evaluation of suspected chronic or disseminated candidiasis in immunocompromised patients (HIV, chemotherapy, transplant) alongside culture and fungal biomarkers
- Assessment of patients with unexplained chronic gastrointestinal symptoms — bloating, dysbiosis, or food intolerances — where intestinal candida overgrowth is suspected in integrative or functional practice
- Work-up of chronic fatigue, 'brain fog', or systemic inflammatory symptoms attributed to candida-related complex or dysbiosis, interpreted within a broader clinical and microbiome assessment
- Monitoring response to antifungal therapy in patients with documented elevated titres and clinical candidiasis
- Screening in patients with conditions predisposing to candida overgrowth: prolonged antibiotic use, corticosteroid therapy, uncontrolled diabetes, or impaired cell-mediated immunity
Sample collection and turnaround
Sample type
Blood (serum)
Fasting required
No
Collection method
Venipuncture at patient service centre
Turnaround
3–5 business days
Collection notes
Phlebotomy at a Quest patient service centre; no special preparation required. Avoid testing shortly after IVIG infusion, which will spuriously elevate IgG.
Specimen requirements
Minimum 1 mL serum (gel separator acceptable). Separate from cells and refrigerate or freeze if testing is delayed. Record any recent antifungal or immunoglobulin therapy on the requisition.
What can affect Candida Antibodies results?
Effective antifungal treatment reduces fungal burden and may lower antibody titres over time; test before starting therapy or interpret trends during treatment carefully.
Patients with severe T-cell or B-cell defects may mount blunted or absent antibody responses despite active infection, so seronegative results do not exclude candidiasis in the immunocompromised.
Antibodies to other fungi (Aspergillus, endemic mycoses) may cross-react with Candida antigens in some assays, potentially producing false-positive or elevated results.
Heavy colonisation in the absence of true infection can drive antibody production, particularly IgA, so elevated titres do not prove pathogenic overgrowth without clinical correlation.
IVIG contains pooled antibodies, including anti-Candida IgG, and will transiently elevate measured IgG titres; avoid testing shortly after IVIG infusion.
This rare genetic syndrome features chronic mucocutaneous candidiasis and robust antibody responses; markedly elevated Candida antibodies in a young patient with endocrinopathy should prompt APECED consideration.
What do Candida Antibodies results mean?
Elevated
IgM elevation suggests acute or recent infection; IgG elevation reflects chronic, recurrent, or past infection; IgA elevation indicates mucosal immune activation or barrier compromise. High titres across all three classes may be seen in chronic disseminated candidiasis or APECED. In functional medicine contexts, elevated IgA or IgG is sometimes interpreted as evidence of intestinal overgrowth, but this remains contested and should be correlated with stool culture, symptoms, and response to dietary or antifungal intervention.
Normal
Negative or low-titre antibodies are reassuring in the absence of clinical candidiasis but do not rule out localised mucosal infection that has not yet elicited a systemic immune response. Candida carriage is universal, so some low-level antibody is often detectable.
Reduced
Absent or very low antibodies are typical in individuals with minimal Candida exposure or in the setting of severe immunodeficiency. A negative result does not exclude candidiasis in immunocompromised patients who cannot mount an antibody response.
Note: Candida antibody serology is neither sensitive nor specific for invasive candidiasis — culture, histopathology, beta-D-glucan, and mannan antigen are preferred for systemic infection. Antibody results must be interpreted with the clinical picture, culture data, and immune status. The concept of 'intestinal candida overgrowth' as a cause of systemic symptoms is not universally accepted in mainstream gastroenterology, and elevated antibodies alone should not drive aggressive antifungal therapy without corroborative findings.
Frequently asked questions
IgM antibodies appear first during acute infection, IgG antibodies reflect past or chronic exposure and persist for months to years, and IgA antibodies are produced at mucosal surfaces and indicate local immune activation in the gut or other mucosa.
How to access the Candida Antibodies test
The Candida Antibodies reference page is free and open to all practitioners. Create a free practitioner account to see pricing, save tests to your list, and generate requisition forms. Verification takes 1–2 business days.
Create Free AccountAbout this page
Published: October 7, 2026
Last reviewed: October 7, 2026
- Pappas PG, et al. Clinical practice guideline for the management of candidiasis: 2016 update by the Infectious Diseases Society of America. Clin Infect Dis. (2016)
- Mikulska M, et al. Invasive candidiasis: update on diagnosis and treatment. Eur J Intern Med. (2021)
- Kumamoto CA. Inflammation and gastrointestinal Candida colonization. Curr Opin Microbiol. (2011)
- Husebye ES, et al. Clinical manifestations and management of patients with autoimmune polyendocrine syndrome type I. J Intern Med. (2009)
This content is for licensed healthcare practitioners only and does not constitute medical advice. Clinical decisions should be based on the full clinical picture and not on any single test result.